Eli Lilly and Company is unveiling its new 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, which will be available for $499 per month using its new Zepbound Self Pay Journey Program. 1 The ...

In terms of competition, there are currently only two other IL-23 inhibitors approved in the US besides Tremfya – Eli Lilly’s Omvoh (mirikizumab) and AbbVie’s Skyrizi (risankizumab). Both drugs ...

Mirikizumab is an investigational monoclonal antibody that binds to the p19 subunit of interleukin 23. It is being studied for the treatment of immune diseases, including psoriasis, ulcerative ...

Switching between infliximab biosimilar SB2 and the reference product did not affect clinical disease activity or safety in IBD patients. No significant changes were observed in clinical outcomes ...

It is not known whether Omvoh (mirikizumab-mrkz) is safe to receive while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy may ...

Ozempic Approval Expanded to Include T2D Patients With Chronic Kidney Disease Omvoh (mirikizumab-mrkz) Humanized immunoglobulin G4 monoclonal antibody that selectively binds to the p19 subunit of ...

Medical media enhances clinical practice, education, and patient engagement in gastroenterology and hepatology. Providers should understand their roles as consumers, contributors, and creators to ...

In the phase 3 VIVID-1 study, patients with moderately to severely active CD who were randomly assigned to Omvoh (mirikizumab-mrkz, Lilly) received 900 mg IV induction at 0, 4 and 8 weeks ...

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including the formation of ALS United, global sleep study results from IKEA and FDA approval of EMBLAVEO™.

Study Rundown: Dermatomyositis is an autoimmune condition driven by type I interferon dysregulation. Current treatments fail to provide effective symptom control, highlighting the need for targeted ...

Some of the notable drug approvals that occurred in January 2025. Omvoh (mirikizumab-mrkz) Humanized immunoglobulin G4 monoclonal antibody that selectively binds to the p19 subunit of human ...